Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current Issue
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Snippets
Special Article
Specialty Interface
Studies
Study Letter
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Systematic Reviews and Meta-analyses
Systematic Reviews and Meta-analysis
Tables
Technology
Therapeutic Guideline-IADVL
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF

Translate this page into:

Letter in Response to Previous Publication
ARTICLE IN PRESS
doi:
10.25259/IJDVL_237_2022

Intravenous pulsed corticosteroids for leprosy neuritis: Logical or irrational?

Department of Dermatology, Venereology & Leprology, Postgraduate Institute of Medical Education & Research, Chandigarh, Chandigarh, India
Department of Dermatology, Shalby Hospital, SAS Nagar, Punjab, India
Corresponding Author: Dr. Tarun Narang, Associate Professor, Department of Dermatology, Venereology & Leprology, Postgraduate Institute of Medical Education & Research, Chandigarh, Chandigarh, India. narangtarun@yahoo.co.in
Licence
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Mehta H, Narang T, Dogra S, Kumar B. Intravenous pulsed corticosteroids for leprosy neuritis: Logical or irrational?. Indian J Dermatol Venereol Leprol doi: 10.25259/IJDVL_237_2022

Sir,

We read with interest the letter by Lugão et al. “Methylprednisolone pulse therapy for leprosy neuritis: A retrospective study with sensory testing and peripheral nerve ultrasonography correlation”,1 describing the successful use of suprapharmacological dose of methylprednisolone given intravenously for leprous neuritis. We critically reviewed this publication and the existing literature to discern whether this was a prudent therapeutic choice.

The publication is unclear about the inclusion criteria. Five patients were administered steroid pulse as the initial treatment, two received it after two months and several others after up to 72 months of oral steroid therapy. However, in Table 1 “months of prednisolone use before pulses” has been mentioned twice with varying figures.

It is imperative to know which signs/symptoms the authors wished to ameliorate and how were they monitored. It is very important to fix the duration of therapy- the ‘end point’- and not–up to 72 months of oral steroids and then with an average of 25 pulses- making a total duration of eight years.

In the absence of this information, at least the signs reflected by sensory testing worsened significantly in 20% of the patients. The observed reduction of hypervascularity on ultrasonography in the nerve strangely did not reflect the corresponding reduction in its diameter.

Neuropathy in leprosy is the basic pathology that needs corticosteroids only during the pain of acute neuritis or significant nerve function impairment of recent onset. Continuation of high doses of oral steroids up to 80 mg/day for as long as 72 months without considering dose reduction or any steroid-sparing agent defies all pharmacological recommendations and also those of any leprosy expert group. In patients with prolonged neuritis as in those with persistent reaction, other causes of recalcitrance like drug resistance should have been considered.

Claimed reduction in the dose of thalidomide may not be relevant as thalidomide is not recommended for the treatment of leprosy neuritis. That the maximum dose of 200 mg given for patients with erythema nodosum leprosum is inadequate is another issue that needs attention.

Adverse effects are associated with prolonged steroid use, especially adrenal suppression, and the I/V administration of steroids restricts this approach to only specialised centres. Further, the use of pulse therapy in patients with neuropathy associated with diabetes may be imprudent, as steroids worsen diabetes and subsequently neuropathy. So, the inference that reduction of steroid dose after pulse therapy in diabetics may be beneficial based on the observations on only four patients may be too premature. The authors also used an arbitrary modification of the established pulse regimen without giving any valid reason.

In the TRIPOD-3 study, systemic corticosteroids did not significantly impact the course of nerve function impairment because of spontaneous improvement.2 A randomized controlled double-blind trial comparing methylprednisolone pulse therapy and oral steroids showed no lasting difference between the two regimens by day 337.3

The biological half-life of methylprednisolone is 12–36 hours, hence the administration of pulse provides suprapharmacological levels for three days and ineffective levels during the rest of the month. Rao et al. compared three steroid regimens in leprosy patients having type 1 reaction with neuritis and concluded that a longer duration was more effective than the higher dose.4 Mahajan et al. administered dexamethasone pulse therapy in three patients of erythema nodosum leprosum, unresponsive to oral prednisolone at 80 mg daily.5 However, early remission of reaction had to be maintained with oral azathioprine, suggesting that the action of pulse is short-lived. The persistent need for pulse therapy for up to 33 months in the present study further undermines its real utility.1

It is important to remember that neuritis is not the sole manifestation of leprosy reactions, hence choosing therapy only on the basis of this one manifestation is not a judicious approach. It would be very informative to know how the authors continued labelling these patients as ‘pure leprous neuritis’, and did not consider ‘neuropathic pain’, long after the completion of multidrug therapy in any of them. While oral prednisolone given for short periods appears to be mostly safe in relation to reactivation of leprosy, similar safety data is unavailable for their long-term use in high doses.

In conclusion, current literature does not support the use of pulsed corticosteroids in leprosy neuritis.

Declaration of patient consent

Patient’s consent not required as there are no patients in this study.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

  1. , , , , , . Methylprednisolone pulse therapy for leprosy neuritis: A retrospective study with sensory testing and peripheral nerve ultrasonography correlation. Indian J Dermatol Venereol Leprol. 2021;88:114-6.
    [CrossRef] [PubMed] [Google Scholar]
  2. , , , , , , et al.. Treatment with corticosteroids of long-standing nerve function impairment in leprosy: A randomized controlled trial (TRIPOD 3) Lepr Rev. 2003;74:311-8.
    [PubMed] [Google Scholar]
  3. , , , , , , et al.. A phase two randomised controlled double blind trial of high dose intravenous methylprednisolone and oral prednisolone versus intravenous normal saline and oral prednisolone in individuals with leprosy type 1 reactions and/or nerve function impairment. PLoS Negl Trop Dis. 2011;5:e1041.
    [CrossRef] [PubMed] [Google Scholar]
  4. , , , . Multi-centre, double blind, randomized trial of three steroid regimens in the treatment of type-1 reactions in leprosy. Lepr Rev. 2006;77:25-33.
    [PubMed] [Google Scholar]
  5. , , , . Pulse dexamethasone, oral steroids and azathioprine in the management of erythema nodosum leprosum. Lepr Rev. 2003;74:171-4.
    [PubMed] [Google Scholar]

Fulltext Views
1,695

PDF downloads
7
View/Download PDF
Download Citations
BibTeX
RIS
Show Sections